Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIOB · Entity 2247 | Executive Vice President | November 11, 2021 | November 15, 2021 |
| Telesis Bio Inc.TBIO · Entity 15606 | Director | July 06, 2023 | May 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date November 11, 2021 · Filed November 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 4,593.3476 |
Ending reported balance
After 2021-11-12 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2021-11-11 · Exercise / conversion · Acquired 613 · Balance 5,206.3476 Row 2 · 2021-11-11 · Exercise / conversion · Acquired 500 · Balance 5,706.3476 Row 3 · 2021-11-11 · Exercise / conversion · Acquired 433 · Balance 6,139.3476 Row 4 · 2021-11-11 · Sale · Disposed 433 · Balance 5,706.3476 Row 5 · 2021-11-11 · Sale · Disposed 613 · Balance 5,093.3476 Row 6 · 2021-11-11 · Sale · Disposed 500 · Balance 4,593.3476 Row 7 · 2021-11-12 · Exercise / conversion · Acquired 600 · Balance 5,193.3476 Row 8 · 2021-11-12 · Exercise / conversion · Acquired 2,400 · Balance 7,593.3476 Row 9 · 2021-11-12 · Exercise / conversion · Acquired 1,800 · Balance 9,393.3476 Row 10 · 2021-11-12 · Sale · Disposed 4,800 · Balance 4,593.3476 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.00 to $750.61, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $524.30 · Expires 2030-09-02 | Direct | 1,300 |
Reported balance
After 2021-11-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-11-11 · Exercise / conversion · Disposed 433 · Balance 1,300 F2: The option, representing a right to purchase a total of 1,733 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $333.34 · Expires 2029-09-03 | Direct | 1,671 |
Reported balance
After 2021-11-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-11-11 · Exercise / conversion · Disposed 1,113 · Balance 1,671 F3: The option, representing a right to purchase a total of 2,784 shares, became exercisable in five equal annual installments beginning on September 3, 2020, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $326.15 · Expires 2028-09-04 | Direct | 1,200 |
Reported balance
After 2021-11-12 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-11-12 · Exercise / conversion · Disposed 1,800 · Balance 1,200 F4: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $215.98 · Expires 2027-09-05 | Direct | 600 |
Reported balance
After 2021-11-12 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-11-12 · Exercise / conversion · Disposed 2,400 · Balance 600 F5: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $159.32 · Expires 2026-09-07 | Direct | 0 |
Reported balance
After 2021-11-12 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-11-12 · Exercise / conversion · Disposed 600 · Balance 0 F6: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.00 to $750.61, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option, representing a right to purchase a total of 1,733 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted.
F3: The option, representing a right to purchase a total of 2,784 shares, became exercisable in five equal annual installments beginning on September 3, 2020, which was the first anniversary of the date on which the option was granted.
F4: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted.
F5: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted.
F6: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted.
Telesis Bio Inc.
Report date July 06, 2023 · Filed May 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,769 |
Ending reported balance
After 2024-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-06 · Grant · Acquired 46,752 · Balance 121,363 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through such date, 100% of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. Row 2 · 2024-05-01 · Grant · Acquired 36,406 · Balance 157,769 F2: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through each applicable date, 16,165 of the RSUs shall vest on January 1, 2025, and 20,241 of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2033-07-06 | Direct | 70,129 |
Reported balance
After 2023-07-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-06 · Grant · Acquired 70,129 · Balance 70,129 F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2034-05-01 | Direct | 30,362 |
Reported balance
After 2024-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-01 · Grant · Acquired 30,362 · Balance 30,362 F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through such date, 100% of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
F2: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through each applicable date, 16,165 of the RSUs shall vest on January 1, 2025, and 20,241 of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2024 Filed May 3, 2024 19:13 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantStock Option (right to buy) · Derivative | 30,362 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0000950170-24-053135 · ownership.xml · derivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,362 Underlying: Common Stock · 30,362 shares Expires 2034-05-01 F3 · derivative.exercise_date: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. Read SEC document |
| May 01, 2024 Filed May 3, 2024 19:13 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantCommon Stock | 36,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-053135 · ownership.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,769 F2 · shares: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through each applicable date, 16,165 of the RSUs shall vest on January 1, 2025, and 20,241 of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. Read SEC document |
| July 06, 2023 Filed May 3, 2024 19:13 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantStock Option (right to buy) · Derivative | 70,129 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000950170-24-053135 · ownership.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,129 Underlying: Common Stock · 70,129 shares Expires 2033-07-06 F3 · derivative.exercise_date: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. Read SEC document |
| July 06, 2023 Filed May 3, 2024 19:13 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantCommon Stock | 46,752 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-053135 · ownership.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,363 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through such date, 100% of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 16:38 UTC | Telesis Bio Inc. DNAY · Entity 15606 | GrantStock Option (right to buy) · Derivative | 111,917 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001209191-22-043010 · doc4.xml · derivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,917 Underlying: Common Stock · 111,917 shares Expires 2032-07-20 F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan) through each applicable vesting date, one thirty-sixth (1/36th) of the Shares subject to the Option shall vest in equal monthly installments following the Grant Date on the same day of the month as the Grant Date. "Grant Date" shall mean July 20, 2022. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 16:38 UTC | Telesis Bio Inc. DNAY · Entity 15606 | GrantCommon Stock | 74,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043010 · doc4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,611 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Codex DNA, Inc.'s (the "Issuer") Common Stock. Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Sock Incentive Plan) through each such date, one third (1/3rd) of the RSUs shall vest annually following the Grant Date on the same day of the month as the Grant Date over three (3) years. "Grant Date" shall mean July 20, 2022. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 15 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,400 | $0.00 Strike: $215.98 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 14 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 2,400 shares Expires 2027-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,800 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 13 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 1,800 shares Expires 2028-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 4,800 | $750.05 | $3,600,240.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 10 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593.3476 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.00 to $750.61, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,800 | $326.15 | $587,070.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 9 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,393.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,400 | $215.98 | $518,352.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 8 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,593.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $159.32 | $95,592.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 7 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,193.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,113 | $0.00 Strike: $333.34 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 12 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 Underlying: Bio-Rad A Common Stock · 1,113 shares Expires 2029-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 2,784 shares, became exercisable in five equal annual installments beginning on September 3, 2020, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 433 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · derivative · entry 11 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Bio-Rad A Common Stock · 433 shares Expires 2030-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 1,733 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 500 | $750.00 | $375,000.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593.3476 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 613 | $748.84 | $459,038.92 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,093.3476 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 433 | $748.08 | $323,918.64 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,706.3476 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 433 | $524.30 | $227,021.90 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,139.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 500 | $333.34 | $166,670.00 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,706.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 613 | $333.34 | $204,337.42 |
DisclosureSEC source: 0001062993-21-010826 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,206.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:38 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008416 · form4.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 7, 2016, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 7, 2016, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:38 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $806.32 | $240,283.36 |
DisclosureSEC source: 0001062993-21-008416 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593.3476 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:38 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008416 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,891.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · derivative · entry 9 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 05, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $819.70 | $244,270.60 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · nonDerivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,291.3476 Read SEC document |
| September 05, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · nonDerivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,589.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · derivative · entry 8 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 04, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $819.70 | $244,270.60 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,989.3476 Read SEC document |
| September 04, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,287.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 557 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · derivative · entry 7 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,671 Underlying: Bio-Rad A Common Stock · 557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 2,784 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 2,784 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 252 | $819.70 | $206,564.40 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,687.3476 Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 16:06 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 557 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008352 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,939.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:10 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 433 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008254 · form4.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Bio-Rad A Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:10 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 150 | $825.77 | $123,865.50 |
DisclosureSEC source: 0001062993-21-008254 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382.3476 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:10 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008254 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,532.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 14:39 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 600 | $792.58 | $475,548.00 |
DisclosureSEC source: 0001062993-21-007992 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,099.3476 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 17:40 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad A Common Stock | 423 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,699.3476 Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · derivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 246 | $641.53 | $157,816.38 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122.3476 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $641.50 to $641.92, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 734 | $640.78 | $470,332.52 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,368.3476 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $640.24 to $641.19, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 220 | $639.62 | $140,716.40 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,102.3476 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $639.16 to $640.14, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,200 | $159.32 | $191,184.00 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,322.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:55 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000047 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:55 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $505.02 | $150,495.96 |
DisclosureSEC source: 0001812865-20-000047 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122.3476 Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:55 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000047 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,420.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 07, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · derivative · entry 9 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. F5 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 07, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $484.23 | $144,300.54 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · nonDerivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,820.3476 Read SEC document |
| September 07, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · nonDerivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,118.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · derivative · entry 8 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.